Home › Funds › BOONE CAPITAL MANAGEMENT LLC › BBIO
BOONE CAPITAL MANAGEMENT LLC position in BBIO
BRIDGEBIO PHARMA INC · Health Care
BOONE CAPITAL MANAGEMENT LLC reported holding 277,433 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$18.3M, representing 4.85% of its reported portfolio and ranking #12 among its reported holdings. BOONE CAPITAL MANAGEMENT LLC has disclosed BBIO holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How BOONE CAPITAL MANAGEMENT LLC's BBIO position evolved
BOONE CAPITAL MANAGEMENT LLC first disclosed a stake in BBIO in Q3 2023 at 313,381 shares (US$8.3M). The position peaked in Q2 2026 at 339,720 shares, worth US$25.3M. Across 7 filings, BOONE CAPITAL MANAGEMENT LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 277,433 shares valued at US$18.3M — a reduction of -62,287 shares quarter over quarter.. Notable position changes include a 41% increase in Q4 2023 (shares fell 23% over the following quarter), a 60% trim in Q4 2025 (shares fell 3% over the following quarter), a 48% increase in Q2 2026 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 313.38K | $8.26M | New |
| Q4 2023 | 440.85K | $17.80M | Add |
| Q3 2025 | 460.28K | $23.91M | New |
| Q4 2025 | 184.96K | $14.15M | Reduce |
| Q1 2026 | 228.83K | $16.99M | Add |
| Q2 2026 | 339.72K | $25.30M | Add |
| Q3 2026 | 277.43K | $18.26M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 40 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$957.7M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 14.56M sh · $957.70M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.25M sh · $937.45M · Q3 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.79M sh · $644.33M · Q3 2026
- Two Sigma Investments 3.66M sh · $240.83M · Q3 2026
- Aisling Capital Management LP 3.09M sh · $203.30M · Q3 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 104.89M sh · $162.63M · Q3 2026
- Paradigm Biocapital Advisors LP 2.35M sh · $154.49M · Q3 2026
- SC US (TTGP), LTD. 1.86M sh · $122.41M · Q3 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.39M sh · $91.65M · Q3 2026
More on BOONE CAPITAL MANAGEMENT LLC
FAQ
How long has BOONE CAPITAL MANAGEMENT LLC held BBIO?
BOONE CAPITAL MANAGEMENT LLC has disclosed BBIO holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is BOONE CAPITAL MANAGEMENT LLC's current position in BBIO?
As of Q3 2026, BOONE CAPITAL MANAGEMENT LLC holds 277.43K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $18.26M, representing 4.85% of its reported portfolio and ranking #12.
Has BOONE CAPITAL MANAGEMENT LLC been buying or selling BBIO?
In the latest 13F filing (Q3 2026), BOONE CAPITAL MANAGEMENT LLC reduced its position in BBIO. The position peaked in Q2 2026 at 339.72K shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.